The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Official Title: A Phase 2, Multicenter, Single-arm, Open Label Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Study ID: NCT02124668
Brief Summary: The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
Detailed Description:
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Site GE99503, Tbilisi, , Georgia
Site GE99502, Tbilisi, , Georgia
Site RU70002, Moscow, , Russian Federation
Site RU70003, Moscow, , Russian Federation
Name: Medical Director
Affiliation: Astellas Pharma Europe B.V.
Role: STUDY_DIRECTOR